Sleeve lobectomy after neoadjuvant therapy for non-small cell lung cancer
Comparative Analysis of Minimally Invasive and Open Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC: A Multicenter Retrospective Evaluation of Surgical Outcomes
This will see if minimally invasive sleeve lobectomy (VATS or RATS) works as well or better than open thoracotomy for adults with non-small cell lung cancer who received pre-surgery (neoadjuvant) treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Shanghai Chest Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT07135856 on ClinicalTrials.gov |
What this trial studies
This is a retrospective, multicenter cohort study collecting surgical and oncologic outcomes from adults with NSCLC who received neoadjuvant therapy and underwent sleeve lobectomy. The analysis compares minimally invasive approaches (VATS or RATS) to open thoracotomy for perioperative and postoperative metrics such as complications, operative complexity, and length of stay. Oncologic endpoints include margin status, extent of lymph node dissection, recurrence-free survival, and overall survival with a minimum 12-month follow-up or until death. Data are pooled from high-volume thoracic centers including Shanghai Chest Hospital and collaborating hospitals to clarify whether minimally invasive techniques provide comparable safety and cancer control in the context of modern multimodal therapy.
Who should consider this trial
Good fit: Adults (≥18) with histologically confirmed non-small cell lung cancer who received neoadjuvant therapy and underwent sleeve lobectomy with curative intent at a participating center, with complete perioperative records and at least 12 months of follow-up, are the ideal candidates for inclusion.
Not a fit: Patients with metastatic (stage IV) disease, those who had sublobar resections or pneumonectomy, those who did not receive neoadjuvant therapy, or those with incomplete records or lost follow-up are unlikely to benefit from this analysis.
Why it matters
Potential benefit: If successful, the findings could support wider use of minimally invasive sleeve lobectomy to reduce complications and speed recovery while maintaining cancer control.
How similar studies have performed: Smaller single-center series and case reports have shown that minimally invasive sleeve lobectomy can be feasible and safe in selected patients, but robust multicenter data after neoadjuvant therapy remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed NSCLC * Undergoing sleeve lobectomy with curative intent * Receipt of neoadjuvant therapy (chemotherapy, immunotherapy, target therapy, etc.) * Surgical approach: either minimally invasive (VATS or RATS) or open thoracotomy * Availability of complete perioperative and follow-up data (minimum 12-month follow-up or until death) * Signed informative consent Exclusion Criteria: * Sublobar resections (e.g., segmentectomy) or pneumonectomy * Absence of neoadjuvant therapy * Purely diagnostic surgical procedures * Incomplete medical records or lost to follow-up * Metastatic (stage IV) disease at time of surgery
Where this trial is running
Shanghai, Shanghai Municipality
- Shanghai Chest Hospital — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Study coordinator: Xinghua Cheng, M.D., Ph.D.
- Email: chengxinghua_001@163.com
- Phone: 86+17701681215
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.